This protocol covers the management of low-risk primary myelofibrosis in patients who present with symptomatic splenomegaly and/or significant disease-related symptoms requiring active treatment despite low-risk disease classification.
The patient has primary myelofibrosis stratified as low-risk, with clinically meaningful splenomegaly and/or accompanying symptoms. Symptomatic burden in the setting of low-risk disease is the defining feature that indicates the need for intervention at this stage.
In this setting, management is built around an established cytoreductive approach. Further options and the complete selection algorithm — including when clinical trial enrollment is appropriate — are detailed in the full protocol.
The clinical objective is meaningful improvement: control of cytosis (reduction of leukocytosis and/or thrombocytosis) and measurable reduction of splenomegaly.
DOI: 10.1182/blood.2022017423